Pegfilgrastim

Evidence Level: L5

Predicted Indications: 2

Pegfilgrastim

Pharmacist Assessment Report

Pegfilgrastim: From an Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Pegfilgrastim is a PEGylated recombinant G-CSF analogue marketed in India in 13 single-ingredient injectable products. The licence records compiled for this report do not state an approved indication. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy (and the broader term diabetic retinopathy), but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not stated in the available licence records
Predicted New Indication	Severe nonproliferative diabetic retinopathy
TxGNN Prediction Score	0.9989
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (13 of 13) – CDSCO approval status is not included in this data
Number of Listed Products	13 (valid: 13)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, pegfilgrastim is a long-acting PEGylated form of granulocyte colony-stimulating factor (G-CSF). It stimulates the growth and mobilisation of neutrophils and haematopoietic progenitor cells. Its mechanistic relationship to diabetic retinopathy has not been established.

Two speculative links can be drawn. First, dysfunction of bone marrow-derived progenitor cells is thought to impair vascular repair in diabetes, and G-CSF might influence this process. Second, neutrophil-mediated inflammation contributes to retinal vascular damage. The second point cuts the other way: G-CSF-induced neutrophilia could worsen retinal inflammation and vascular injury. The direction of effect is therefore unclear.

The two predicted indications (severe nonproliferative diabetic retinopathy and its parent term, diabetic retinopathy) overlap, so they are not independent pieces of evidence. No clinical or preclinical data were available to confirm or refute a therapeutic effect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

All 13 licences are valid single-ingredient injectable products. The licence records do not include approved indication text. The five main authorisations are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
173956	Pegstim Injection (Zydus Cadila)	Prefilled syringe, 0.6 ml injection	Not stated
87425	Filcad P Injection (Cadila Pharmaceuticals Ltd)	Prefilled syringe, 0.6 ml injection	Not stated
206706	Sfil Peg 6mg Injection (Sarabhai Chemicals Ltd)	Prefilled syringe, injection	Not stated
174482	Peg-ReliGrast Injection (Reliance Life Sciences)	Prefilled syringe, injection	Not stated
151911	Neupeg 6mg Injection (Intas Pharmaceuticals Ltd)	Vial, injection	Not stated

Cytotoxicity

Pegfilgrastim is a supportive-care growth factor, not an antineoplastic drug, so a cytotoxicity assessment does not apply.

Safety Considerations

Drug Interactions: The interaction screening identified 147 potential interacting drugs. The 20 entries retrieved were all rated Moderate. They include:
- Cytotoxic and antineoplastic agents such as paclitaxel, mercaptopurine, azacitidine, arsenic trioxide, trimetrexate, altretamine and asparaginase
- Targeted agents such as abemaciclib, acalabrutinib and avapritinib
- Immunotherapies and biologics such as aldesleukin, alemtuzumab and belantamab mafodotin
- Radiopharmaceuticals and radioimmunotherapy agents such as iobenguane (I-131), tositumomab, ibritumomab tiuxetan and fludeoxyglucose (18F)
- Others, including levamisole and pegvaliase

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction relies entirely on a high model score (0.9989). There are no clinical trials, no literature, and no mechanism of action data. The biological direction of effect is also uncertain, because G-CSF-driven neutrophilia could aggravate retinal inflammation.

To proceed, the following is needed:

Package insert warnings and contraindications for the Indian products, which are required before safety screening can start
Confirmed mechanism of action data and the approved indications for the marketed products
Preclinical or mechanistic evidence on G-CSF effects in the diabetic retina, including whether the effect is beneficial or harmful
A literature and trial search specific to G-CSF or pegfilgrastim and diabetic retinopathy
An assessment of whether the injectable route and dosing are compatible with a retinal indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.